Secondary Logo

Journal Logo

Dendritic Cell Therapy in Transplantation, Phenotype Governs Destination and Function

Samy, Kannan P., MD1; Brennan, Todd V., MD, MS2

doi: 10.1097/TP.0000000000002238
Commentaries
Free

Dendritic cell (DC)-based cell therapy is a potential treatment in solid organ transplantation. In particular, recipient-derived DCs show tolerogenic potential in animal models and are being applied in a clinical Phase I study in kidney transplanted patients. These pioneer results will be important for future efforts in clinical trials of DCs but also to better define biological properties.

1Department of Surgery, Indiana University School of Medicine, IN.

2Department of Surgery, Duke University School of Medicine, Durham, NC.

Received 16 February 2018. Revision received 13 March 2018.

Accepted 15 March 2018.

The authors declare no conflicts of interest.

K.S. and T.B. participated in the writing of the article.

Correspondence: Todd V. Brennan, MD, MS, Duke University Medical Center, 330 Trent Drive, Box 3512, Durham, NC 27710. (todd.brennan@duke.edu).

Although pharmacological methods are the mainstay for transplant immunosuppression, cell-based therapies are being increasingly studied as a potential alternative. Currently available immunosuppressive medications lack specificity, leaving transplant recipients vulnerable to infection, malignancy, and drug-related toxicities while still being susceptible to chronic rejection. Donor-specific tolerance would be clearly superior to global immunosuppression yet remains an elusive goal. Recent advances in cell-based therapies along with an improved understanding of central and peripheral tolerance mechanisms offer new possibilities for donor-specific immunomodulation. Among the many types of cell-based therapies tested to date, some of the most successful thus far have involved donor stem cell transplantation in living-donor kidney transplant recipients.1 However, the need ex vivo cell manipulation along with T-cell depletion and bone marrow conditioning makes these methods arduous for many transplant recipients and impractical for those receiving deceased donor organs. As an alternative cellular therapy, dendritic cells (DCs) are particularly attractive because of their role as central regulators of immune responses.2

In this edition of Transplantation, Rosen and colleagues3 present a comprehensive review of the role DCs play in producing allograft tolerance, highlighting recent studies demonstrating the utility of recipient-derived DCs loaded with donor antigen, rather than donor-derived DCs for transplant immunotherapy. Recipient-derived DCs present donor antigen in the context of self major histocompatibility complex (indirect presentation), which in the setting of transplantation produces stronger allospecific effector responses when compared with direct presentation of donor major histocompatibility complex.4 Thus, autologous DCs are attractive because they also generate potent regulatory T-cell responses when compared with suppressive macrophages or myeloid derived suppressor cells.5 Murine models of allotransplantation demonstrate that these effects further extend graft survival with minimal pharmacologic immunosuppression.6-8 Self-DCs may also be easier to maintain in an immature phenotype after transfer as they will not themselves be targeted by pathways of direct antigen presentation that can lead to their elimination or, even worse, induce their maturation and sensitize the recipient against donor antigen.

As illustrated in the review by Rosen et al, the surface phenotype and location of DCs influence their effects on the immune system. Considered to be the most potent of the antigen-presenting cell types, DCs are highly mobile sentinels of the innate immune system that collect peripheral antigens and present them to the adaptive immune system. The context in which DCs present antigen is regulated by a complex array of stimulatory and inhibitory signals that orchestrate the direction and magnitude of the immune response. In the presence of local inflammatory signals, tissue resident DCs mature (mDCs) and express increased levels of antigen-presenting molecules, costimulation molecules, and inflammatory cytokines that differentiate T cells into effector phenotypes. In the absence of inflammation, immature DCs (imDCs), including migratory conventional DCs (SIRPα+, CD11c+, B220neg) and plasmacytoid DCs (PDCA-1+, CD11c+, B220+) with decreased antigen-presenting potential, help maintain self-tolerance to peripheral antigens.

Although the migratory routes of DCs are incompletely understood, there is evidence that their phenotype governs their destination and ultimately their function in regulating immune responses (Figure 1). In the setting of inflammatory signals, mDCs in the periphery also upregulate chemokine receptors (CCR) (eg, CCR7 and CXCR4) and adhesion molecules (eg, LFA1). Dendritic cells expressing CCR7 and CXCR4 chemotaxis to LNs through attraction by their ligands (C-C motif chemokine ligand [CCL]21 and CCL19, and CXCL12, respectively) and LFA1/ICAM-1 interactions which are critical to DC adherence and residence in LNs where they stimulate and polarize T cells.9,10 However, the roles of these molecules are complex and “semimature” DCs expressing CCR7, yet low levels of CD40 and B7 have been found to have a role in steady-state migration of skin DCs even in the absence of inflammation.11

FIGURE 1

FIGURE 1

As discussed by Rosen et al, intrathymic imDCs can produce tolerogenic responses. In the absence of inflammation, imDCs that express CCR9 and CCR2, but have low levels of CCR7 and CXCR4, can bypass the lymph nodes en route to the central venous system. The circulating imDCs can then home to the thymus driven by CCR9/CCL25 interactions12 and migrate into the thymus though processes involving very late antigen 4 and its ligand vascular cell adhesion molecule-1.12,13 Although the thymus has mechanisms for maintaining self-tolerance through its intrinsic expression of peripheral self-antigens regulated by the autoimmune regulator protein,14 peripheral sampling of self-antigens by immature DCs provides a supplemental mechanism for maintaining tolerance to peripheral tissue antigens.15 The question remains whether these tolerance mechanisms can translate into effective cellular therapies for clinical transplantation.

If DC localization and function is determined by phenotype, then methods of isolating and preparing recipient DCs with the appropriate markers is critical to determining their capacity for immune modulation. The studies presented in the review by Rosen et al demonstrate the potential for DC-based tolerance induction. Although clearly demonstrated in murine models, further mechanistic understanding in the human immune system is needed to translate these concepts into clinical feasibility, whether they be for the purpose of immune-inhibition in transplantation and autoimmune disease, or immune stimulation for tumor therapy.16 Already, the administration of autologous tolerogenic DC preparations is beginning to be tested in clinical trials for the treatment of autoimmune diseases,15 and for immunosuppressive therapy in the setting of living-donor renal transplantation in the European ONE Study.17 However, additional questions remain that may further improve efficacy in the setting of transplantation. These include refining methods for induction and maintenance of imDCs, including ex vivo versus in vivo manipulation, the source for donor antigen, the incorporation of induction protocols, timing of therapy, and the durability of such cell-based treatments. As the marshals of the adaptive immune system, DCs hold significant potential for cell-based immune therapies. Further, clinical studies will be required to determine if these concepts and methods can effectively translate to the human immune system which can vary greatly between individuals based on their immunologic history and physiology.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors thank Megan Llewellyn for graphical assistance.

Back to Top | Article Outline

REFERENCES

1. Scalea JR, Tomita Y, Lindholm CR, et al. Transplantation tolerance induction: cell therapies and their mechanisms. Front Immunol. 2016;7:87.
2. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol. 2011;23:252–263.
3. Rosen SJ, Harris PE, Hardy MA. State of the art: role of the dendritic cell in induction of allograft tolerance. Transplantation. 2018;102:1603–1613.
4. Brennan TV, Jaigirdar A, Hoang V, et al. Preferential priming of alloreactive T cells with indirect reactivity. Am J Transplant. 2009;9:709–718.
5. Carretero-Iglesia L, Bouchet-Delbos L, Louvet C, et al. Comparative study of the immunoregulatory capacity of in vitro generated tolerogenic dendritic cells, suppressor macrophages, and myeloid-derived suppressor cells. Transplantation. 2016;100:2079–2089.
6. Baas MC, Kuhn C, Valette F, et al. Combining autologous dendritic cell therapy with CD3 antibodies promotes regulatory T cells and permanent islet allograft acceptance. J Immunol. 2014;193:4696–4703.
7. Segovia M, Louvet C, Charnet P, et al. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation. Am J Transplant. 2014;14:1021–1031.
8. Tsang JYS, Tanriver Y, Jiang S, et al. Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. Transpl Immunol. 2009;21:203–209.
9. Kabashima K, Shiraishi N, Sugita K, et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol. 2007;171:1249–1257.
10. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5:617–628.
11. Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004;21:279–288.
12. Scimone ML, Aifantis I, Apostolou I, et al. A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus. Proc Natl Acad Sci U S A. 2006;103:7006–7011.
13. Bonasio R, Scimone ML, Schaerli P, et al. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006;7:1092–1100.
14. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science. 2002;298:1395–1401.
15. Domogalla MP, Rostan PV, Raker VK, et al. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol. 2017;8:1764.
16. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation. 2008;85:1513–1522.
17. ONE Study ATDC Trial (ONEatDC). A Phase I/II Monocentric Trial of Cellular Immunotherapy Based on Autologous Tolerogenic Dendritic Cells (ATDCs) Administration in Patients With Renal Insufficiency Receiving as First Transplantation a Kidney Transplant From a Living-donor. Available from https://clinicaltrials.gov/ct2/show/NCT02252055. Accessed March 11, 2018.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.